Megace Dose Assessment: 400mg/10mL, 2 teaspoons PO BID
The prescribed dose of Megace 400mg/10mL, 2 teaspoons (10mL = 800mg) twice daily for a total of 1600mg/day is NOT appropriate and exceeds recommended dosing.
Correct Dosing Based on FDA Label and Guidelines
The FDA-approved formulation you're describing appears to be Megace ES (concentrated formula at 125mg/mL), not the regular suspension 1. This is a critical distinction:
Megace ES (125mg/mL concentration):
- Recommended dose: 625mg/day = 5mL (1 teaspoon) ONCE daily 1
- Your order of 2 teaspoons BID would deliver 2500mg/day - approximately 4 times the recommended dose
If using regular Megace suspension (40mg/mL):
- Standard effective dose: 400-800mg/day 1
- Your order of 10mL BID from a 40mg/10mL suspension would only deliver 800mg/day total, which falls within range
Evidence-Based Dosing Recommendations
For medroxyprogesterone acetate (MPA) as appetite stimulant:
- Minimum effective dose: 200mg/day 2
- Studied range: 300-1200mg/day 3
- Most trials used 300-500mg twice daily for 6-12 weeks 3
For megestrol acetate (different drug):
Critical Safety Concerns
You must be aware of serious adverse effects, particularly at high doses:
- Thromboembolic events: 1 in 6 patients 4
- Increased mortality: 1 in 23 patients 4
- Edema, adrenal insufficiency 5
- Impotence, vaginal spotting 3
The 2017 ESPEN guidelines explicitly state: "suggest considering progestins to increase appetite...but to be aware of potential serious side effects (e.g. thromboembolism)" 3.
Recommended Action
HOLD this order and clarify:
- Which formulation is being used (Megace ES 125mg/mL vs regular 40mg/mL)?
- Intended indication (appetite stimulation in cancer cachexia vs other)?
- Correct the dose:
- If Megace ES: 625mg (5mL) once daily
- If regular MPA suspension: 400-500mg (10-12.5mL) once or twice daily
- Maximum studied dose: 1200mg/day, but no benefit above 800mg/day
Clinical Pearls
- MPA increases appetite but does NOT increase lean body mass - only fat mass increases 3
- Effect on quality of life is inconsistent 3
- Should only be used in advanced cancer patients with months-to-weeks life expectancy where appetite is important for quality of life 4
- Monitor for thromboembolism, edema, hyperglycemia (especially in dialysis patients) 6, 7
- Recent data shows increased meningioma risk with prolonged MPA exposure (>4 years or age >31) 8, 9
The dose as written is unsafe and requires immediate clarification and correction.